[(BACKGROUND,determined by,multiple factors,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(radiotherapy,may,may used,1.0), (radiotherapy,may,may used for tumour shrinkage,1.0), (radiotherapy,may,may used for tumour shrinkage prior,1.0), (tumour,remains following,systemic therapy,1.0), (primary tumour,remains following,therapy,1.0), (radiotherapy,may,may used for tumour shrinkage prior to surgery,1.0), (tumour,remains following,therapy,1.0), (primary tumour,remains,unresectable,1.0), (primary tumour,remains following,systemic therapy,1.0), (tumour,remains,unresectable,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(disease,is,present,1.0), (radiotherapy,is,reserved,1.0), (metastatic disease,is,When present,1.0), (radiotherapy,is generally reserved for,management of symptoms,1.0), (locoregional radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (radiotherapy,is reserved for,management,1.0), (locoregional radiotherapy,is reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is,reserved,1.0), (radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is,generally reserved,1.0), (radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is reserved for,management,1.0), (disease,is,When present,1.0), (locoregional radiotherapy,is reserved for,management of symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management of symptoms,1.0), (metastatic disease,is,present,1.0), (locoregional radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0), (locoregional radiotherapy,is generally reserved for,management,1.0), (radiotherapy,is generally reserved for,management of tumour-related symptoms,1.0)][(We,reviewed,our experience,1.0), (We,reviewed,our experience of high-dose radiotherapy,1.0), (We,reviewed,our experience of radiotherapy,1.0)][(We,reviewed,our experience,1.0), (We,reviewed,our experience of high-dose radiotherapy,1.0), (We,reviewed,our experience of radiotherapy,1.0)][(We,reviewed,our experience,1.0), (We,reviewed,our experience of high-dose radiotherapy,1.0), (We,reviewed,our experience of radiotherapy,1.0)][(patients,is with,unresected locally advanced breast cancer,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patients,were stratified based on,presence of metastatic disease,1.0), (Patients,were stratified based on,presence,1.0), (Patients,were stratified based on,presence of disease at presentation,1.0), (Patients,were,stratified,1.0), (Patients,were stratified based on,presence of metastatic disease at presentation,1.0), (Patients,were stratified based on,presence at presentation,1.0), (Patients,were stratified based on,presence of disease,1.0)][(Patient demographics,were,recorded,1.0)][(Forty-three cases,were,analyzed,0.6336231364591115), (cases,were,analyzed,0.6336231364591115)][(Forty-three cases,were,analyzed,0.6336231364591115), (cases,were,analyzed,0.6336231364591115)][(follow-up,was,25 months,1.0), (follow-up,was,25 months from diagnosis,1.0), (Median follow-up,was,25 months,1.0), (Median follow-up,was,25 months from diagnosis,1.0)][(follow-up,was,25 months,1.0), (follow-up,was,25 months from diagnosis,1.0), (Median follow-up,was,25 months,1.0), (Median follow-up,was,25 months from diagnosis,1.0)][(follow-up,was,25 months,1.0), (follow-up,was,25 months from diagnosis,1.0), (Median follow-up,was,25 months,1.0), (Median follow-up,was,25 months from diagnosis,1.0)][(follow-up,was,25 months,1.0), (follow-up,was,25 months from diagnosis,1.0), (Median follow-up,was,25 months,1.0), (Median follow-up,was,25 months from diagnosis,1.0)][(metastatic disease,with cases is,56 %,1.0), (24 cases,is with,metastatic disease on presentation,1.0)][(metastatic disease,with cases is,56 %,1.0), (24 cases,is with,metastatic disease on presentation,1.0)][(24 applicable cases,of 13 is,54 %,1.0), (Ulceration,improved in,54 %,1.0), (bleeding,improved following,radiotherapy,1.0), (bleeding,improved in,54 %,1.0), (Ulceration,improved following,radiotherapy,1.0)][(24 applicable cases,of 13 is,54 %,1.0), (Ulceration,improved in,54 %,1.0), (bleeding,improved following,radiotherapy,1.0), (bleeding,improved in,54 %,1.0), (Ulceration,improved following,radiotherapy,1.0)][(24 applicable cases,of 13 is,54 %,1.0), (Ulceration,improved in,54 %,1.0), (bleeding,improved following,radiotherapy,1.0), (bleeding,improved in,54 %,1.0), (Ulceration,improved following,radiotherapy,1.0)][(24 applicable cases,of 13 is,54 %,1.0), (Ulceration,improved in,54 %,1.0), (bleeding,improved following,radiotherapy,1.0), (bleeding,improved in,54 %,1.0), (Ulceration,improved following,radiotherapy,1.0)][(24 applicable cases,of 13 is,54 %,1.0), (Ulceration,improved in,54 %,1.0), (bleeding,improved following,radiotherapy,1.0), (bleeding,improved in,54 %,1.0), (Ulceration,improved following,radiotherapy,1.0)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)][(patients,is with,LABC,1.0), (role,is in,patients with LABC,1.0), (symptom control,good response in,most patients in study,0.8724352182509769), (Radiotherapy,good response in,patients in study,0.6740404803211208), (Radiotherapy,good response in,most patients in study,0.6740404803211208), (response,is in,most patients,1.0), (most patients,is in,study,1.0), (Radiotherapy,response in,patients in study,0.6740404803211208), (symptom control,response in,most patients in study,0.8724352182509769), (Radiotherapy,response in,most patients in study,0.6740404803211208), (symptom control,response in,patients in study,0.8724352182509769), (symptom control,good response in,patients in study,0.8724352182509769)]